Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 28Rectal Neoplasms 25Stomach Neoplasms 24Colonic Neoplasms 13Neoplasms 3Neoplasm Metastasis 3Adenocarcinoma 3Gastrointestinal Neoplasms 2Waldenstrom Macroglobulinemia 1Turcot syndrome 1Recurrence 1Rcctal Cancer 1Peripheral Nervous System Diseases 1Metastatic HER2 Positive Gastroesophageal Junction Cancer 1Locally Advanced Rectal Cancer (LARC) 1Locally Advanced Rectal Cancer 1Locally Advanced Gastric Cancer 1Locally Advanced Colorectal Cancer 1Intestinal Neoplasms 1HER2-positive Locally Advanced Resectable Gastric Cancer 1HER2-positive Colorectal Cancer 1Gastrointestinal Diseases 1Gastric Cancer Stage 1Gastric Adenocarcinoma 1Esophageal Neoplasms 1Digestive System Diseases 1Colorectal Cancer Metastatic 1Colonic Diseases 1Carcinoma 1Adenocarcinoma of the Lower Rectum 1

Interventions

XELOX 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Rcctal Cancer × XELOX × Clear all
NCT06808412 2025-02-05

To Explore the Efficacy of Sintilimab Combined With Bevacizumab in Rectal Cancer

Xijing Hospital of Digestive Diseases

Phase 2 Recruiting
118 enrolled

Rcctal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡